A retrospective inpatient study counted lorazepam among commonly administered medicines. Incomplete standardized response documentation limited comparative efficacy and safety conclusions.
The analysis included 191 children and adolescents and 1,238 one-time or as-needed doses for agitation. Antipsychotics were the largest class, while lorazepam accounted for 235 doses, or nineteen percent.
The study examined additional medication, restraint or seclusion, and documented adverse reactions as practical outcome indicators. Most doses appeared tolerated in the available records.
Repeat medication may reflect persistent symptoms, delayed onset, a new episode, or local practice. Restraint and seclusion are influenced by staffing and policy as well as drug response. They are not standardized direct measures of symptom change.
The authors noted inconsistent pre- and post-treatment assessment and possible adverse-reaction underreporting. Some diphenhydramine use also could not be confidently classified as agitation treatment rather than prevention of another drug’s effects.
Use dose counts to describe exposure, not the number of distinct patients benefiting from a drug. The paper cannot establish lorazepam’s comparative effectiveness from administration frequency alone. Meaningful review requires the symptom timeline, reason for each dose, concurrent medications, documented response, and monitoring.
Original analysis of the supplied journal article, identified as PMC13229529.